Vertex Pharma (VRTX) Tops Q2 EPS by 19c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Vertex Pharma (VRTX) Tops Q2 EPS by 19c; Raises Outlook
July 26, 2018 9:03 AM EDT
Morgan Stanley raised its price target on Vertex (NASDAQ: VRTX) to $211.00 (from $207.00) while maintaining a Overweight rating.
...
More
July 26, 2018 8:44 AM EDT
RBC Capital raised its price target on Vertex (NASDAQ: VRTX) to $203.00 (from $202.00) while maintaining an Outperform rating.
Analyst Brian Abrahams commented, "Despite rising expectations into 2Q, an impressive beat for VRTX's CF franchise."
...
More
July 26, 2018 7:11 AM EDT
BMO Capital raised its price target on Vertex (NASDAQ: VRTX) to $204.00 (from $191.00) while maintaining an Outperform rating following results.
Analyst Do Kim commented, "We raise our revenue estimates and target price to $204 from $191, following stellar 2Q18 CF revenues that easily exceeded our and... More
July 26, 2018 7:07 AM EDT
UBS raised its price target on Vertex (NASDAQ: VRTX) to $188.00 (from $183.00) while maintaining a Neutral rating.
...
More
July 26, 2018 6:59 AM EDT
Oppenheimer raised its price target on Vertex (NASDAQ: VRTX) to $200.00 (from $180.00) while maintaining an Outperform rating following results.
Analyst Hartaj Singh commented, "Vertex (VRTX) reported 2Q18 sales/earnings and provided a business update to investors on 7/25. Based on the company's robust results and... More
